Chemistry:SDB-005
SDB-005 (also known as NA-PINAC using systematic EUDA nomenclature)[1] is an indazole-based synthetic cannabinoid that has been sold online as a designer drug.[2] It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-005 is the indazole core analog of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.

The code number SDB-005 was originally used by Samuel D. Bannister for a different compound, the N-phenyl instead of N-benzyl analogue of SDB-006, pictured. It is systematically named PH-PICA (Phen-1-yl 1-Pentyl-1H-indazole-3-carboxamide. This compound is a potent agonist of the CB1 receptor (Ki = 21 nM) and CB2 receptor (Ki = 140 nM)[3] but has significant chemical differences; an indazole ring (instead of indole ring), a carboxamide linker (instead of carboxylate ester) and linked phenyl (instead of naphtyl) group).
However, SDB-005 was subsequently used as the name for the indazole-3-napthyl-carboxylate compound when it was sold in Europe as a designer drug. Because of this, it was entered into the EMCDDA synthetic drug database under this name.[4] The UK Forensic Early Warning System reported a detection of SDB-005 in December 2017 as the first occurrence of naphthalen-1-yl-1-pentyl-1H-indazole-3-carboxylate (NA-PINAC) in the UK.[5] Many online sources now list SDB-005 as naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate (NA-PINAC).[6][7]
Consequently, there are now two distinct, yet fairly closely related cannabinoid compounds, which may both be referred to under the code SDB-005.
See also
References
- ↑ "EMCDDA framework and practical guidance for naming synthetic cannabinoids". Drug Testing and Analysis 15 (3): 255–276. March 2023. doi:10.1002/dta.3403. PMID 36346325. https://www.euda.europa.eu/drugs-library/emcdda-framework-and-practical-guidance-naming-synthetic-cannabinoids_en.
- ↑ "SDB-005". Cayman Chemical. https://www.caymanchem.com/app/template/Product.vm/catalog/15389.
- ↑ "The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse". ACS Chemical Neuroscience 4 (7): 1081–92. July 2013. doi:10.1021/cn400035r. PMID 23551277.
- ↑ EWS_EU: Neue Psychoaktive Substanzen, April 2015
- ↑ "Annual report on the Home Office forensic early warning system (FEWS), 2017 to 2018" (in en). https://www.gov.uk/government/publications/forensic-early-warning-system-fews-annual-report/annual-report-on-the-home-office-forensic-early-warning-system-fews-2017-to-2018.
- ↑ "TRC-S210000-1G" (in en). https://www.lgcstandards.com/US/en/SDB-005/p/TRC-S210000. "naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate"
- ↑ "SDB-005 Monograph". The Drug Enforcement Administration's Special Testing and Research Laboratory (SWGDrug). 2016-04-04. https://www.swgdrug.org/Monographs/SDB-005.pdf. "naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate"
